NSTC-HAS 111-2927-I-037-501(NSTC-HAS 111-2927-I-037-501) Funder: MTA
Subjects:
Pharmacology and pharmacy
Pharmacognosy
Our research group previously identified graviquinone (1) as a promising antitumor
metabolite that is formed in situ when the antioxidant methyl caffeate scavenges free
radicals. Furthermore, it exerted a DNA damaging effect on cancer cells and a DNA
protective effect on normal keratinocytes. To expand and explore chemical space around
qraviquinone, in the current work we synthesized 9 new alkyl‐substituted derivatives
and tested their in vitro antitumor potential. All new compounds bypassed ABCB1‐mediated
multidrug resistance and showed highly different cell line specificity compared with
1. All compounds were more potent in MDA‐MB‐231 than on MCF‐7 cells. The n‐butyl‐substituted
derivatives 2 and 8 modulated the cell cycle and inhibited the ATR‐mediated phosphorylation
of checkpoint kinase‐1 in MCF‐7 cells. As a significant expansion of our previous
findings, our results highlight the potential antitumor value of alkyl‐substituted
graviquinone derivatives.